World Aids Day 2010 Poster

presented a new drug against kidney cancer in Buenos Aires

It is Avastin and approval period by the Anmat. Life extension achieved patients without disease progression .

Bevacizumab is a new generic drug is indicated for the treatment of advanced kidney cancer, which manages to prolong the life of the patient without disease progression.

According to the statement in the presentation made in Buenos Aires, is in the approval period by the National Drug, Food and Technology (ANMAT).

Canton Enrique Diaz, chief of Oncology Fundaleu said that "patients treated with bevacizumab experienced a higher frequency of tumor shrinkage, with a tolerability profile very acceptable. "

Canton Díaz said that" drug significantly improves the results obtained in the treatment of this disease and is established as an important option in the treatment of advanced kidney cancer. "

drug approval is based on a medical trial is in phase III and showed that patients with advanced kidney cancer who received bevacizumab in combination with interferon, lived nearly twice as long without progression of the disease than those who received only interferon.

Source : Télam